Incidence and survival of benign, borderline, and malignant meningioma patients in the United States from 2004 to 2018

Abstract

Meningioma is the most common primary central nervous system tumor, and its incidence is increasing. A systematic epidemiological and clinical analysis is required to better estimate its public health impact and understand its prognostic factors. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2018 for all types of meningiomas without an age restriction.Age-adjusted incidence rates (IRs) and 95% confidence intervals were estimated according to sex, age, race, ethnicity, and tumor location. Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to analyze the overall survival (OS). The competing risk regression model of Fine-Gray was used to analyze cause-specific survival. Data from a total of 109 660 meningioma patients were analyzed. A majority of patients were older than 60 years, and only 0.41% of patients were 0-19 years. The meningioma IRs were higher in females, Black, and non-Hispanic patients than in males, White, and Hispanic patients, respectively, and IRs increased with age. The ratio of IRs for females to males was 2.1 and also increased with age, peaking at 3.6 in the 45-49-year-old group. Older and male patients with all types of meningiomas, Black patients with benign and borderline meningiomas, and patients with larger borderline and malignant meningiomas showed poorer prognosis. For all meningioma types, surgical resection improved survival. The reported incidence rates and survival trends covered all demographics and subtypes of meningiomas. Older age, male sex, Black race, and tumor size may be important prognostic factors for meningioma cases, and tumor resection can substantially improve survival among meningioma patients.

Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: A competing-risk regression model for survival analysis

“…Similar to this, other investigations in LGGs based on CBTRUS or SEER have found either no change in survival with adjuvant therapy or a tendency toward poorer survival in patients receiving adjuvant therapy (2). This may be the unspecific information from the SEER database, which does not define the type of chemotherapy or radiation used or whether it was adjuvant or salvage treatment (29). Alternatively, since this is a retrospective study, doctors frequently choose highrisk LGGs patients for postoperative adjuvant radiotherapy and/or chemotherapy.…”

Epidemiology and survival of non-malignant and malignant meningiomas in middle-aged females, 2004-2018

“…With an incidence rate (IR) of 8.81 per 100 000 person-years, meningioma was the most prevalent primary intracranial tumor, accounting for 38.3% of all brain tumor types recorded in the US from 2013 to 2017 ( 1 ). Meningiomas are more likely to affect women than males ( 1 , 2 ). They are more common in the elderly, especially those aged > 65 years ( 3 ).…”

“…They are more common in the elderly, especially those aged > 65 years ( 3 ). In addition, 90% of meningiomas are supratentorial, and the remaining 10% are spinal and infratentorial ( 1 , 2 ). Several risk factors for meningioma have been reported, including ionizing radiation and hormonal abnormalities ( 4 , 5 ).…”

“…Meningiomas are more common in women than in men, particularly in middle-aged women ( 2 ). According to the CBTRUS data, patients aged 35–54 years had the highest female-to-male incidence ratio of 3.29 times ( 1 ).…”

Postoperative peritumoral edema can predict the prognosis in intracranial meningioma with preoperative peritumoral edema

“…Meningiomas are the most common primary intracranial neoplasms accounting for 37.6% of all central nervous system (CNS) tumor [1][2]. The cause of meningioma is not totally clear [3][4]. Most meningiomas are generally considered benign but approximately (20%) are assigned to Word Health…”